See more : Dominion Energy, Inc. (DCUE) Income Statement Analysis – Financial Results
Complete financial analysis of Faes Farma, S.A. (FAE.MC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Faes Farma, S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Next Digital Limited (0282.HK) Income Statement Analysis – Financial Results
- Shanghai Lonyer Fuels Co., Ltd. (603003.SS) Income Statement Analysis – Financial Results
- Agratio urban design Inc. (3467.T) Income Statement Analysis – Financial Results
- Mapletree Logistics Trust (M44U.SI) Income Statement Analysis – Financial Results
- Exxaro Tiles Limited (EXXARO.NS) Income Statement Analysis – Financial Results
Faes Farma, S.A. (FAE.MC)
About Faes Farma, S.A.
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 451.17M | 438.75M | 398.56M | 380.24M | 357.40M | 324.31M | 274.58M | 228.64M | 204.72M | 191.74M | 180.39M | 176.11M | 190.22M | 202.51M | 131.41M | 194.18M | 185.94M | 185.19M | 166.45M | 163.01M | 173.34M |
| Cost of Revenue | 154.05M | 156.74M | 146.16M | 140.40M | 129.99M | 120.18M | 96.44M | 77.44M | 70.96M | 65.71M | 65.75M | 63.05M | 74.33M | 83.94M | 842.00K | 79.28M | 70.58M | 0.00 | 0.00 | 58.60M | 61.31M |
| Gross Profit | 297.12M | 282.02M | 252.40M | 239.84M | 227.41M | 204.13M | 178.14M | 151.19M | 133.77M | 126.04M | 114.65M | 113.06M | 115.90M | 118.57M | 130.56M | 114.90M | 115.37M | 185.19M | 166.45M | 104.41M | 112.03M |
| Gross Profit Ratio | 65.86% | 64.28% | 63.33% | 63.08% | 63.63% | 62.94% | 64.88% | 66.13% | 65.34% | 65.73% | 63.55% | 64.20% | 60.93% | 58.55% | 99.36% | 59.17% | 62.04% | 100.00% | 100.00% | 64.05% | 64.63% |
| Research & Development | 5.20M | 3.72M | 3.89M | 3.25M | 4.18M | 2.82M | 3.18M | 2.59M | 1.99M | 674.00K | 1.38M | 1.38M | 1.36M | 1.30M | 0.00 | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 33.24M | 28.89M | 27.93M | 20.06M | 21.77M | 18.45M | 19.31M | 14.96M | 16.77M | 16.08M | 13.90M | 13.61M | 0.00 | 0.00 | 0.00 | 0.00 | 52.29M | 46.10M | 39.28M | 39.12M | 38.10M |
| Selling & Marketing | 24.13M | 23.58M | 21.38M | 21.13M | 26.53M | 20.32M | 13.99M | 11.01M | 10.46M | 9.38M | 12.12M | 14.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.37M | 52.47M | 49.32M | 41.19M | 48.30M | 38.77M | 33.29M | 25.97M | 27.23M | 25.46M | 26.02M | 27.94M | 0.00 | 0.00 | 0.00 | 0.00 | 52.29M | 46.10M | 39.28M | 39.12M | 38.10M |
| Other Expenses | 234.55M | -2.17M | 100.33M | 102.83M | 95.49M | -21.19M | -20.73M | -5.86M | -2.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 297.12M | 179.59M | 153.53M | 147.27M | 147.97M | 141.58M | 127.41M | 102.96M | 92.07M | 89.69M | 85.53M | 89.73M | 101.05M | 96.03M | 62.34M | 37.16M | 26.32M | 36.16M | 37.56M | 32.10M | 31.56M |
| Cost & Expenses | 451.17M | 336.33M | 299.69M | 287.67M | 277.96M | 261.75M | 223.84M | 180.40M | 163.02M | 155.39M | 151.28M | 152.78M | 175.38M | 179.97M | 63.18M | 116.44M | 96.90M | 36.16M | 37.56M | 90.70M | 92.87M |
| Interest Income | 1.08M | 253.00K | 23.00K | 156.00K | 59.00K | 76.00K | 209.00K | 185.00K | 174.00K | 228.00K | 259.00K | 222.00K | -191.00K | 743.00K | 10.11M | 1.28M | 5.26M | 2.83M | 2.23M | 2.41M | 7.82M |
| Interest Expense | 684.00K | 263.00K | 216.00K | 266.00K | 51.00K | 256.00K | 211.00K | 7.00K | 78.00K | 874.00K | 1.67M | 2.28M | 2.16M | 3.83M | 2.18M | 9.01M | 2.31M | 906.00K | 2.62M | 4.57M | 2.34M |
| Depreciation & Amortization | 19.40M | 19.27M | 17.26M | 14.83M | 12.68M | 10.25M | 8.46M | 5.65M | 5.77M | 6.38M | 7.61M | 8.33M | 9.12M | 9.04M | 5.61M | 8.57M | 14.88M | 0.00 | 0.00 | 16.15M | 15.66M |
| EBITDA | 122.93M | 121.35M | 110.84M | 100.26M | 87.22M | 72.47M | 58.39M | 52.24M | 45.40M | 40.04M | 33.47M | 29.86M | 23.66M | 32.32M | 30.08M | 31.28M | 36.83M | 39.83M | 22.75M | 47.59M | 40.46M |
| EBITDA Ratio | 27.25% | 27.69% | 28.77% | 27.78% | 25.60% | 22.39% | 20.68% | 23.46% | 23.26% | 22.20% | 20.11% | 17.71% | 12.60% | 15.96% | 15.00% | 18.30% | 19.40% | 12.23% | 13.67% | 29.19% | 23.34% |
| Operating Income | 103.75M | 101.92M | 98.44M | 90.79M | 78.81M | 62.01M | 49.35M | 47.98M | 41.84M | 36.18M | 28.67M | 22.86M | 14.85M | 23.28M | 14.10M | 26.96M | 21.19M | 22.65M | 22.75M | 31.45M | 24.80M |
| Operating Income Ratio | 23.00% | 23.23% | 24.70% | 23.88% | 22.05% | 19.12% | 17.97% | 20.99% | 20.44% | 18.87% | 15.90% | 12.98% | 7.81% | 11.50% | 10.73% | 13.89% | 11.40% | 12.23% | 13.67% | 19.29% | 14.31% |
| Total Other Income/Expenses | -896.00K | -77.97M | -4.88M | -7.69M | -5.27M | -828.00K | -204.00K | -2.17M | -2.47M | -3.60M | -4.92M | -4.08M | -4.39M | -3.09M | -5.41M | -9.01M | -2.71M | -906.00K | -2.62M | -4.57M | -2.34M |
| Income Before Tax | 102.85M | 101.42M | 93.99M | 84.88M | 74.18M | 61.73M | 50.53M | 46.07M | 39.23M | 32.75M | 24.20M | 19.25M | 12.38M | 19.46M | 11.92M | 17.95M | 18.88M | 21.74M | 20.13M | 26.88M | 22.46M |
| Income Before Tax Ratio | 22.80% | 23.12% | 23.58% | 22.32% | 20.75% | 19.03% | 18.40% | 20.15% | 19.16% | 17.08% | 13.41% | 10.93% | 6.51% | 9.61% | 9.07% | 9.25% | 10.15% | 11.74% | 12.10% | 16.49% | 12.96% |
| Income Tax Expense | 11.16M | 11.92M | 10.78M | 11.51M | 10.15M | 9.93M | 8.31M | 9.48M | 8.87M | 7.42M | 1.59M | -267.00K | -1.80M | -547.00K | -6.24M | -1.66M | -3.27M | -1.03M | -3.14M | 3.09M | 2.93M |
| Net Income | 91.90M | 89.50M | 82.39M | 72.55M | 63.96M | 51.59M | 42.22M | 36.59M | 30.36M | 25.33M | 22.61M | 19.52M | 14.18M | 20.00M | 18.16M | 19.62M | 22.15M | 22.77M | 23.27M | 23.79M | 19.53M |
| Net Income Ratio | 20.37% | 20.40% | 20.67% | 19.08% | 17.90% | 15.91% | 15.38% | 16.00% | 14.83% | 13.21% | 12.53% | 11.08% | 7.45% | 9.88% | 13.82% | 10.10% | 11.91% | 12.30% | 13.98% | 14.60% | 11.27% |
| EPS | 0.30 | 0.29 | 0.28 | 0.26 | 0.23 | 0.19 | 0.15 | 0.14 | 0.12 | 0.10 | 0.09 | 0.09 | 0.06 | 0.09 | 0.10 | 0.11 | 0.12 | 0.15 | 0.09 | 0.09 | 0.08 |
| EPS Diluted | 0.30 | 0.29 | 0.27 | 0.25 | 0.23 | 0.19 | 0.15 | 0.14 | 0.12 | 0.10 | 0.09 | 0.09 | 0.06 | 0.09 | 0.10 | 0.11 | 0.12 | 0.15 | 0.09 | 0.09 | 0.08 |
| Weighted Avg Shares Out | 310.48M | 305.64M | 291.46M | 279.86M | 273.28M | 266.00M | 258.07M | 251.58M | 251.73M | 245.96M | 237.70M | 225.87M | 218.82M | 219.00M | 210.65M | 172.86M | 172.86M | 153.65M | 254.50M | 254.50M | 254.50M |
| Weighted Avg Shares Out (Dil) | 310.73M | 305.92M | 304.82M | 292.03M | 273.28M | 276.24M | 267.99M | 261.26M | 261.41M | 254.50M | 241.60M | 225.87M | 218.82M | 219.00M | 210.65M | 172.86M | 172.86M | 153.65M | 254.50M | 254.50M | 254.50M |
Source: https://incomestatements.info
Category: Stock Reports